Updated June 2026 · ClinicalTrials.gov
Fondazione IRCCS Policlinico San Matteo di Pavia
15 clinical trials · 15 recruiting · OTHER
Fondazione IRCCS Policlinico San Matteo di Pavia has 15 clinical trials registered on ClinicalTrials.gov, with 15 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.
About Fondazione IRCCS Policlinico San Matteo di Pavia\'s Trial Portfolio
Fondazione IRCCS Policlinico San Matteo di Pavia is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.
15 of Fondazione IRCCS Policlinico San Matteo di Pavia's 15 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.
Fondazione IRCCS Policlinico San Matteo di Pavia's research footprint spans Al Amyloidosis (3 trials), Multiple Myeloma (2), and immune-checkpoint-inhibitors-induced-colitis (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.
is the largest single phase in Fondazione IRCCS Policlinico San Matteo di Pavia's portfolio at 93% of registered trials. The full phase breakdown appears in the sidebar.
Trials by Fondazione IRCCS Policlinico San Matteo di Pavia
Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis
This is a multicentric, observational study, including all European centres willing to take part. The multicentre nature is necessary for enhancing the generalisability of our...
Inside a Neuron - Ex Vivo Evaluation of Cerebral and Cerebellar Neuronal Activity.
Understanding the functioning of human neurons has always been a key element, especially with regard to the translation of the inputs they receive into actions that determine...
Multiple Human Papillomavirus Infections in the Development of CIN
Multiple infections of high-risk genotypes of Human Papillomavirus (HR-HPV) in patients with abnormal cervical cytological or histological findings are detectable in a percentage...
Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Immunoglobulin light chain (AL) amyloidosis is caused by a typically small, minimally proliferating bone marrow plasma cell clone secreting a patient-unique, unstable,...
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS
Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm of the pleural mesothelium, mainly associated to asbestos exposure, still lacking effective therapies....
PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND...
The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial...
Prevalence, Pathogenesis, and Prognosis of Pulmonary Hypertension in Dialysis Patients
This prospective multicenter longitudinal study aims to investigate the prevalence, pathogenesis, and prognosis of pulmonary hypertension in patients with end-stage renal disease...
Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults
After obtaining informed consent, the investigators will recruit 75 patients with T1DM and 75 with LADA with an age ≥ 18 years and ≤ 75 years, of both sexes. All patients will be...
Effect of Two Food Supplements on Lipid Profile in Patients With Mild Hypercholesterolemia
The primary outcome is to evaluate the effect of Cynacol on the change in LDL-C levels compared to Metacol after 90 days of supplementation. The secondary outcomes are to...
SMAtteo COvid19 REgistry (SMACORE)
Since the start of the COVID-19, Italy, and particularly the Northern region, Lombardia, has initially been the centre of the most numerous reports of confirmed cases of COVID-19...
Magnetic Resonance Imaging of the Lung: Non-Oncological Applications
Non-neoplastic pulmonary proliferative diseases are characterized by a complex interaction between proliferating lung cells and a variety of resident and infiltrating host cells,...
Introduction of Polymerase Chain Reaction (PCR) in Microbiology and Parasitology
The goal is to develop molecular systems to support or replace in microscopic characterization and in vitro tests with molecular biology systems capable of improving performance...
Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights...
The Enterovirus genus, belonging to the Picornaviridae family, consists of positively polarized single-stranded RNA viruses classified into the species Enterovirus (EV, comprising...
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains...
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to: 1....
How to Approach a Trial Listing
Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.
Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.
Authoritative Resources
Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.
Frequently Asked Questions
How many clinical trials does Fondazione IRCCS Policlinico San Matteo di Pavia have on ClinicalTrials.gov?
Fondazione IRCCS Policlinico San Matteo di Pavia has 15 clinical trials registered on the federal ClinicalTrials.gov registry, of which 15 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.
What conditions does Fondazione IRCCS Policlinico San Matteo di Pavia study?
Fondazione IRCCS Policlinico San Matteo di Pavia's registered trials cover 20 conditions on ClinicalTrials.gov, led by Al Amyloidosis (3 trials), Multiple Myeloma (2 trials), immune-checkpoint-inhibitors-induced-colitis (1 trial), advanced-melanoma-skin-cancer-non-small-cell-lung-carcinoma-kidney-adenocarcinoma (1 trial), ileo-colitis (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.
How do I join a Fondazione IRCCS Policlinico San Matteo di Pavia clinical trial?
Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.
What does the trial phase mean?
Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.
Where does this trial data come from?
All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.
How This Sponsor Page Is Built
Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.
Other Trial Sponsors
87 trials · 87 recruiting
58 trials · 58 recruiting
48 trials · 48 recruiting
48 trials · 48 recruiting
48 trials · 48 recruiting
47 trials · 47 recruiting
Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."
Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.
Last updated 2026-06-26 · 15 trials tracked for Fondazione IRCCS Policlinico San Matteo di Pavia.